These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 21149652)
1. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. Warren KE; Goldman S; Pollack IF; Fangusaro J; Schaiquevich P; Stewart CF; Wallace D; Blaney SM; Packer R; Macdonald T; Jakacki R; Boyett JM; Kun LE J Clin Oncol; 2011 Jan; 29(3):324-9. PubMed ID: 21149652 [TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. Berg SL; Cairo MS; Russell H; Ayello J; Ingle AM; Lau H; Chen N; Adamson PC; Blaney SM J Clin Oncol; 2011 Jan; 29(3):316-23. PubMed ID: 21149673 [TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial. Fangusaro J; Mitchell DA; Kocak M; Robinson GW; Baxter PA; Hwang EI; Huang J; Onar-Thomas A; Dunkel IJ; Fouladi M; Warren KE Pediatr Blood Cancer; 2021 Feb; 68(2):e28756. PubMed ID: 33025730 [TBL] [Abstract][Full Text] [Related]
4. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Fine HA; Kim L; Albert PS; Duic JP; Ma H; Zhang W; Tohnya T; Figg WD; Royce C Clin Cancer Res; 2007 Dec; 13(23):7101-6. PubMed ID: 18056189 [TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. Kieran MW; Packer RJ; Onar A; Blaney SM; Phillips P; Pollack IF; Geyer JR; Gururangan S; Banerjee A; Goldman S; Turner CD; Belasco JB; Broniscer A; Zhu Y; Frank E; Kirschmeier P; Statkevich P; Yver A; Boyett JM; Kun LE J Clin Oncol; 2007 Jul; 25(21):3137-43. PubMed ID: 17634493 [TBL] [Abstract][Full Text] [Related]
6. A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Kilburn LB; Kocak M; Decker RL; Wetmore C; Chintagumpala M; Su J; Goldman S; Banerjee A; Gilbertson R; Fouladi M; Kun L; Boyett JM; Blaney SM Neuro Oncol; 2015 Feb; 17(2):303-11. PubMed ID: 25431212 [TBL] [Abstract][Full Text] [Related]
7. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Fouladi M; Stewart CF; Olson J; Wagner LM; Onar-Thomas A; Kocak M; Packer RJ; Goldman S; Gururangan S; Gajjar A; Demuth T; Kun LE; Boyett JM; Gilbertson RJ J Clin Oncol; 2011 Sep; 29(26):3529-34. PubMed ID: 21825264 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ J Clin Oncol; 2010 Sep; 28(27):4221-7. PubMed ID: 20713864 [TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. Packer RJ; Rood BR; Turner DC; Stewart CF; Fisher M; Smith C; Young-Pouissant T; Goldman S; Lulla R; Banerjee A; Pollack I; Kun L; Onar-Thomas A; Wu S; Boyett JM; Fouladi M J Neurooncol; 2015 Jan; 121(1):217-24. PubMed ID: 25407389 [TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN). Bukowinski A; Chang B; Reid JM; Liu X; Minard CG; Trepel JB; Lee MJ; Fox E; Weigel BJ Pediatr Blood Cancer; 2021 Apr; 68(4):e28892. PubMed ID: 33438318 [TBL] [Abstract][Full Text] [Related]
11. Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. Robison NJ; Yeo KK; Berliner AP; Malvar J; Sheard MA; Margol AS; Seeger RC; Rushing T; Finlay JL; Sposto R; Dhall G J Neurooncol; 2018 May; 138(1):199-207. PubMed ID: 29427149 [TBL] [Abstract][Full Text] [Related]
12. A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. Hipp SJ; Goldman S; Kaushal A; Krauze A; Citrin D; Glod J; Walker K; Shih JH; Sethumadhavan H; O'Neill K; Garvin JH; Glade-Bender J; Karajannis MA; Atlas MP; Odabas A; Rodgers LT; Peer CJ; Savage J; Camphausen KA; Packer RJ; Figg WD; Warren KE J Neurooncol; 2020 Sep; 149(3):437-445. PubMed ID: 33040274 [TBL] [Abstract][Full Text] [Related]
13. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ; Dhall G; Wu S; Onar A; Boyett JM; Fouladi M Neuro Oncol; 2016 Sep; 18(9):1319-25. PubMed ID: 27022131 [TBL] [Abstract][Full Text] [Related]
14. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Kieran MW; Chi S; Goldman S; Onar-Thomas A; Poussaint TY; Vajapeyam S; Fahey F; Wu S; Turner DC; Stewart CF; Moses M; Packer RJ; Jakacki R; Banerjee A; Boyett JM; Fouladi M; Kun L Childs Nerv Syst; 2015 Sep; 31(9):1433-45. PubMed ID: 26188774 [TBL] [Abstract][Full Text] [Related]
15. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. Dahut WL; Aragon-Ching JB; Woo S; Tohnya TM; Gulley JL; Arlen PM; Wright JJ; Ventiz J; Figg WD J Clin Pharmacol; 2009 Jun; 49(6):650-60. PubMed ID: 19451403 [TBL] [Abstract][Full Text] [Related]
16. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. Akshintala S; Marcus L; Warren KE; Murphy RF; Sissung TM; Srivastava A; Goodspeed WJ; Goodwin A; Brewer CC; Zalewski C; King KA; Kim A; Figg WD; Widemann BC Pediatr Blood Cancer; 2015 Apr; 62(4):603-10. PubMed ID: 25556988 [TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Said R; Kakadiaris E; Piha-Paul S; Fu S; Falchook G; Janku F; Wheler JJ; Zinner R; Hong DS; Kurzrock R; Tsimberidou AM Cancer Chemother Pharmacol; 2016 May; 77(5):1097-102. PubMed ID: 27085994 [TBL] [Abstract][Full Text] [Related]
18. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866 [TBL] [Abstract][Full Text] [Related]
19. Lenalidomide is safe and active in Waldenström macroglobulinemia. Fouquet G; Guidez S; Petillon MO; Louni C; Ohyba B; Dib M; Poulain S; Herbaux C; Martin A; Thielemans B; Brice P; Choquet S; Bakala J; Bories C; Demarquette H; Nudel M; Tournilhac O; Arnulf B; LeGouill S; Morel P; Banos A; Karlin L; Salles G; Leblond V; Leleu X Am J Hematol; 2015 Nov; 90(11):1055-9. PubMed ID: 26284823 [TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]